Is Matinas Biopharma Holdings going out of business?

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) scores 21 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: ROIC: -487.05%

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $761K of cash and short-term investments against $12.0M of annual burn. Adjusted shares outstanding increased 25.9% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

48.3% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: -0.42x (Net Cash)
• ROIC: -487.05%
• Revenue CAGR (3Y): -100.00%
• Shares dilution YoY: 25.93% (YoY)
• Return on Assets: -303.19%
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-07.